• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS

    9/16/25 8:00:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • UNITY VCS provides statistically significant set-up and tear-down efficiencies compared to CONSTELLATION Vision System or CENTURION Vision System1,2
    • Statistically significant reductions in total energy delivered into the eye were observed with UNITY VCS compared to CENTURION Vision System with ACTIVE SENTRY during cataract surgery2
    • Turnover time savings with UNITY VCS allow for more efficient use of the operating room for both cataract and vitreoretinal surgeries1,2

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to CONSTELLATION® Vision System and CENTURION® Vision System with ACTIVE SENTRY ®.1-6 The studies were presented during the 25th Euretina Congress (Paris; 4-7 September), The Retina Society's 58th Annual Scientific Meeting (Chicago; 10-13 September) and the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS; Copenhagen; 12-15 September).

    "We invest heavily in surgical innovation because it's our responsibility as the global leader in eye care to elevate the market and provide Eye Care Professionals with the tools they need the most," said Sean Clark, Vice President and General Manager, Global Surgical Franchise at Alcon. "We listened to the current needs of surgeons, who are looking for solutions to help drive efficiencies. We are proud to demonstrate that UNITY VCS helps do just that with this real-world evidence over our leading CONSTELLATION Vision System and CENTURION Vision System with ACTIVE SENTRY."1,2

    Vitreoretinal and cataract ORs are facing multiple challenges. Globally, the number of age-related macular degeneration (AMD) and diabetic retinopathy patients will increase 46.9% and 55% by 2040 and 2045, respectively.7 Additionally, between 1990 and 2021, the global prevalence of cataracts increased by nearly 138% from 42.3 million to 100.5 million.8 These patient populations are also contending with a 12% decline in ophthalmologists worldwide, leaving fewer Eye Care Professionals to keep up with the growing demand.9 Surgical technologies that can help fill these gaps by supporting workflow efficiencies are critical, and Alcon's latest clinical studies demonstrate commitment to generating these solutions.

    The first study—a prospective, observational, controlled, multi-site time and motion study (total n=179 surgical cases)—used objective, videography-based measurements to directly compare UNITY VCS (n=92) against the CONSTELLATION Vision System (n=87) in vitreoretinal surgery. Investigators assessed the duration of console set-up, intraoperative time and tear-down time of 25-gauge (Ga) vitrectomy surgeries.1 Study results demonstrated UNITY VCS provides a 16% efficiency gain in overall workflow.1 UNITY VCS provides statistically significant efficiencies in console set-up (33%) and tear-down (38%).1

    "Our data demonstrates that the UNITY VCS streamlined platform and integrated controls result in clearly measurable time savings in the overall workflow," said retina surgeon and lead investigator Dr. John Kitchens. "These efficiencies are not just helpful, they are critical for managing OR throughput and maintaining a high standard of care across a demanding surgical schedule."

    The second study presented—an observational, pre–post, multi-site time and motion analysis evaluated console setup and full procedure turnover for cataract surgeries (total n=303 patients) using UNITY VCS with either the Intelligent Sentry handpiece or the ACTIVE SENTRY handpiece (n=142), compared to the CENTURION Vision System with ACTIVE SENTRY handpiece (n=161).2 The results of the study demonstrate that UNITY VCS reduces cataract surgery turnover time by 6%.2 In addition, reductions in total energy into the eye (35%) and ultrasound time (8%), were observed.2

    "An efficient OR set-up has a cascading effect; it enables my staff to stay focused on what truly matters: delivering the best surgical care to our patients without compromising quality," said cataract surgeon and lead investigator Dr. Lawrence Woodard. "Our study demonstrates that UNITY VCS can support efficiency, directly impacting my high-volume practice."

    UNITY VCS is currently available in Australia, Brazil, Canada, Europe, India, Japan and the U.S. For more information, please visit https://www.myalcon.com/professional/unity/.

    Alcon medical device(s) comply with the current legislation for the medical devices. Please refer to relevant products' directions for use or operator's manuals for complete lists of indications, contraindications and warnings.

    Products mentioned may not be approved in all markets; please reach out to your Alcon Representative for questions about availability in your local market.

    This content is intended for Healthcare Professionals (HCPs) only. Please note that product-related promotion of Medical Devices to non-HCPs may be subject to restrictions based on local rules and regulations.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    About UNITY VCS

    The UNITY VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.

    About CENTURION® Vision System

    The CENTURION® Vision System is indicated for emulsification, separation, irrigation, and aspiration of cataracts, residual cortical material and lens epithelial cells, vitreous aspiration and cutting associated with anterior vitrectomy, bipolar coagulation, and intraocular lens injection. Appropriate use of CENTURION® Vision System parameters and accessories is important for successful procedures. Please refer to the Operator's Manual for a complete description of proper use and maintenance, as well as a complete list of contraindications, warnings and precautions.

    About CONSTELLATION® Vision System

    The CONSTELLATION® Vision System is intended to be used in both anterior segment and posterior segment ophthalmic surgery. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.

    *Based on Bench Testing

    Dr. John Kitchens and Dr. Lawrence Woodard are both paid Alcon consultants.

    References

    1. Alcon data on file, 2025. [REF-27910].
    2. Alcon data on file, 2025. [REF-27959].
    3. Alcon data on file, 2024. [REF-24615].
    4. Alcon data on file, 2024. [REF-24379].
    5. Alcon data on file, 2024. [REF-24576].
    6. Alcon data on file, 2024. [REF-24644].
    7. Ben-Arzi A, Ehrlich R, Neumann R. Retinal Diseases: The Next Frontier in Pharmaco- delivery. Pharmaceutics. 2022;14(5):904. Published 2022 Apr 21. doi:10.3390/pharmaceutics14050904
    8. Lin L, Liang Y, Jiang G, Gan Q, Yang T, et al. (2025) Global, regional, and national burden of cataract: A comprehensive analysis and projections from 1990 to 2021. PLOS ONE. 20(6):e0326263. https://doi.org/10.1371/journal.pone.0326263.
    9. Berkowitz ST, Finn AP, Parikh R, Kuriyan AE, Patel S. Ophthalmology Workforce Projections in the United States, 2020 to 2035. Ophthalmology. 2024 Feb;131(2):133-139. doi: 10.1016/j.ophtha.2023.09.018. Epub 2023 Sep 20. PMID: 37739231.

    Connect with us on

    Facebook

    LinkedIn

    X

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250915504763/en/

    Investor Relations

    Dan Cravens, Allen Trang

    + 41 589 112 110 (Geneva)

    + 1 817 615 2789 (Fort Worth)

    [email protected]

    Media Relations

    Steven Smith

    + 41 589 112 111 (Geneva)

    + 1 817 551 8057 (Fort Worth)

    [email protected]

    Get the next $ALC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    8/21/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    3/25/2025Neutral → Buy
    BofA Securities
    1/24/2025$108.00 → $106.00Buy
    Needham
    1/10/2025Neutral → Buy
    Redburn Atlantic
    12/17/2024$103.00 → $108.00Buy
    Needham
    More analyst ratings

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon downgraded by Analyst

    Analyst downgraded Alcon from Overweight to Neutral

    8/21/25 8:12:09 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Deutsche Bank

    Deutsche Bank downgraded Alcon from Buy to Hold

    5/20/25 8:02:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    BTIG Research reiterated coverage on Alcon with a new price target

    BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

    5/14/25 11:06:26 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced, under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day volume weighted average price and a 51% premium to the cl

    9/30/25 8:30:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved

    Proposed Merger Represents a Compelling 59% Premium to the 90-Day VWAP Prior to Announcement STAAR's Business Risks and Challenges are Increasing and Competition is Intensifying China Net Sales, which Represent Approximately Half of STAAR's Consolidated Net Sales, Have Declined Since 2023, and Procedure Volumes Remain Weak Broadwood Partners' Claims Against the Merger are Flawed and Misleading and Reflect a Misunderstanding of STAAR's Standalone Challenges, Value, and Potential Buyer Interest in STAAR STAAR's Stock Traded at $18.49 per Share Prior to Announcement – If the Merger is not Approved, STAAR Expects its Valuation Would Face Considerable Downward Pressure, Especially in Lig

    9/26/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote "AGAINST" Proposed Acquisition by Alcon

    Outlines Its Belief that the Proposed Transaction Is the Product of Bad Timing, a Flawed Process, and Significant Conflicts of Interest Broadwood Believes the Transaction Delivers Less Value than Alternatives, Including a Properly Run Strategic Alternatives Process or Improved Execution as a Standalone Business Sends Letter to STAAR Stockholders Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood"), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) today announced that it has filed a definitive proxy statement and GREEN proxy card with the U.S. Securities and Exchange Commission (the "SEC

    9/24/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    8/19/25 4:31:11 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form DEFM14A filed by Alcon Inc.

    DEFM14A - ALCON INC (0001167379) (Filer)

    8/5/25 7:21:07 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    8/5/25 7:18:06 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ALC
    Leadership Updates

    Live Leadership Updates

    View All

    $ALC
    Financials

    Live finance-specific insights

    View All

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/23 1:35:38 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

    First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

    5/13/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care